Finding the right dose of fulvestrant in breast cancer.
Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may be more effective. The present work summarizes and discusses clinical trials that have aimed to test the benefits of administering fulvestrant at a higher dose. The data support the use of a higher, and more possibly, effective dose of the agent.
Medical Oncology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain. lauraestevez@hospitaldemadrid.com
L
L
Estévez
I
I
Alvarez
I
I
Tusquets
M A
MA
Seguí
M
M
Muñoz
Y
Y
Fernández
A
A
Lluch
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans
D018931:Antineoplastic Agents, Hormonal; D000077267:Fulvestrant; D004958:Estradiol